Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07579754

BetterInfo on Women's PrEP Choices and Outcomes in Malawi

The purpose of this study is to understand PrEP user choices, preferences and implementation impact of the roll-out of long-acting injectable PrEP alongside oral PrEP among women in Blantyre, Malawi.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–110 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Johns Hopkins Research Project Malawi

Blantyre, Malawi

Location status: Recruiting

Location contact

Linda Nyondo-Mipando, PhD, RNM

PRINCIPAL_INVESTIGATOR

Sufia Dadabhai, PhD, MHS

CONTACT

[email protected]

+265 111 811 885

About this study

The study aims to understand PrEP user choices, preferences and implementation impact of the roll-out of long-acting injectable (LAI) PrEP alongside oral PrEP among women in Malawi. The Broad Objective of this study is to use the adapted BetterInfo tracing approach to evaluate PrEP choices and oral and long-acting injectable PrEP use over time among women lost-to-follow up (LTFU) within the prior 2 years in Blantyre, Malawi and preferences for PrEP re-engagement strategies. Concurrently with this tracing approach, the study team will assess decision making among disengaged women and the women's providers.

The study has Specific Objectives:

  • Ascertain clinical and engagement outcomes among disengaged PrEP users
  • Document experiences and perceptions of key stakeholders from PathToScale regarding program implementation and user retention
  • Investigate factors contributing to discontinuation of PrEP
  • Evaluate the impact of BetterInfo tracing approach on re-engaging former PrEP users and improving long term retention outcomes.

These objectives will be achieved through tracing a random sample of women LTFU from oral and injectable PrEP services from implementing sites in Blantyre, Malawi for whom outcomes are unknown, and which are achieved through two data collection activities. The first comprises cross-sectional quantitative survey including stated preference assessments with discontinued (former) PrEP users. The second comprises in-depth qualitative interviews (IDIs) with sub-sets of the traced discontinued PrEP users, as well as healthcare providers/ implementing partner stakeholders. Activities from this study will inform the design of strategies for optimizing PrEP continuation and re-engagement to achieve implementation and prevention impact for women in Malawi.

The study team will utilize epidemiological principles to sample women on PrEP lost to follow-up with unknown outcomes with the purpose of utilizing this sample to re-estimate PrEP outcomes across all women lost on PrEP in the facilities. Using a sampling and tracing approach the study team will then leverage a sequential mixed methods design. First, the study team will conduct a quantitative study among women traced, including a questionnaire, HIV outcomes assessment and stated preference questions. Then a subset of women will be included, alongside healthcare providers, in follow-up qualitative in-depth interviews to gain greater insights into women's PrEP journeys and the circumstances and considerations around discontinuation of PrEP and re-engagement on PrEP. Study processes will take approximately 2 years to successfully trace the targeted sample.

The study design leverages the existing infrastructure from the PathToScale study (NCT06319105) and mimics the approach used in Zambia, with human-centered design adaption from the formative phase of the study. The study team will leverage existing Electronic Medical Records (EMR) from PathToScale at clinics to identify all clients initiating PrEP during the PathToScale study who have become LTFU, (i.e., 3 months late for a return visit) in accordance with Ministry of Health (MOH) guidelines. The list of clients LTFU will be randomly sorted using statistical software and consecutively sampled for tracing; this process will be stratified by site proportional to the number of female PrEP clients.

Additionally, the study team will prospectively screen PrEP clients at clinics prior to loss to follow-up. Potential participants will be informed of the study and confirm follow-up phone contacts for themselves and any other individuals the participant would be comfortable being contacted. The study team will also request permission to share home locator information and if participants are comfortable, the study team will seek the participant's permission for in-person follow-up should the participant be lost to followup (LTFU) and randomly selected for the study. In all cases the study team will attempt to contact via phone a client at least three times prior to initiating home-based tracing and only if verbal consent was indicated for this visit.

The study team will classify the following outcomes of those participants contacted/traced: (1) discontinued PrEP and no longer at increased acquisition risk; (2) discontinued PrEP and remaining at high risk for HIV acquisition; (3) on PrEP but transferred sites/on PrEP at the same site but data error identified; (4) re-initiated PrEP after an interruption; and (5) newly acquired HIV cases (those known to the client already and those identified through the study).

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

The population for this research includes women aged 18 years or older at risk of HIV who initiated injectable or oral PrEP at one of the 20 Blantyre sites supported through PathToScale. PathToScale supports various types of facilities including public health clinics, drop-in centers for prioritized populations (DICs), and private hospitals/clinics.

Those eligible for sampling are as follows:

  • Adult women ≥18 years; and
  • Initiated PrEP (injectable or oral) at the implementing facilities and lost to follow up within prior 2 years prior to sampling; and
  • Lost-to-follow-up (missed their PrEP visit by ≥3 months and for whom outcomes are unknown); and
  • Has a registered phone number for contact

Those eligible for tracing are as follows:

  • Women sampled per eligibility criteria above; and
  • Women who have indicated permission for in-person follow-up

Health Care Providers, Implementing Partners, Ministry of Health (MOH) Stakeholers

  • providers and implementing partners from PathtoScale, and Ministry of Health stakeholders will be consented to participate in in-depth-interviews

Exclusion criteria

Those excluded from sampling or tracing include:

  • Women who have an EMR record of a documented case of discontinuation of PrEP in consultation with a provider; or
  • Women who are known to have died; or
  • Women who have EMR documented transfers out of PathToScale supported facilities; or
  • Women refusing follow-up via phone on their ScanForm; or
  • Women refusing follow-up in person (during phone tracing); or
  • Women who do not speak Chichewa or English; or
  • Men (excluded from client interviews only)

Treatment and study plan

Tracing Strategy

Behavioral

Participants will receive the SoC per national guidelines and the tracing strategy. The purpose of this intervention is to ascertain the PrEP outcome of clients who have become LTFU (3 months late for a follow-up visit. The strategy includes 1) phone tracing and 2) field tracing with consent.

Primary outcomes

  1. PrEP users LTFU (Prep Engagement)

    Time frame: From 3 months LTFU up to 24 months

    • number of PrEP users discontinued PrEP and are no longer at high risk / number of LTFU PrEP users traced.
    • number of PrEP users discontinued PrEP and remain at high risk / number of LTFU PrEP users traced.
    • number of PrEP users on PrEP but transferred site (silent transfers) / number of LTFU PrEP users traced.
    • number of PrEP users back on PrEP but had an interruption / number of LTFU PrEP users traced.
    • number of PrEP users newly acquired HIV / number of LTFU PrEP users traced.
  2. LTFU PrEP users traced who returned (Impact of tracing on return)

    Time frame: 6 months

    Assess the impact of tracing on 6-month return/re-engagement in PrEP care. Measured by the number of LTFU PrEP users traced who returned / number of LTFU PrEP users traced.

Secondary outcomes

  1. Number of clients traced with any drug level in dried blood sample

    Time frame: Immediately after the tracing intervention

    Measured by the number of clients traced with any drug level in their blood / number of PrEP clients traced. PrEP drug blood levels will be measured biologically through dried blood samples among those lost to follow up and traced.

  2. Participant re-engagement preferences estimated by discrete choice experiment

    Time frame: Within 24 months of PrEP LTFU

    Assess preferences through discrete choice experiment methods (best worst scaling) for re-engaging in PrEP care among those at HIV risk. Evaluated using count analysis and best-worst scaling scores for individuals (difference in number of times item scored best and worst number of times item appears and aggregate score for the population (mean population score rescaled to 100, presented as forest plots).

Study contacts

Contact information is provided by the study sponsor or research team.

Amal Abdulrahman, MSPH

CONTACT

[email protected]

+ 1 443-983-4376

Sheree Schwartz, PhD, MPH

CONTACT

[email protected]

+1 443-983-2464

Sponsors and collaborators

Lead sponsor

Johns Hopkins Bloomberg School of Public Health

Other

Collaborators

  • Johns Hopkins Research Project, Malawi
  • Kamuzu University of Health Sciences
  • National Institute of Mental Health (NIMH)
  • Washington University School of Medicine

Registry information

Official study title

BetterInfo Tracing Approach to Evaluate HIV PrEP Choices and Use Over Time Among Women in Blantyre, Malawi

Important dates

Study start
2026
Primary completion
2028
Study completion
2029
First posted
May 12, 2026
Registry last updated
Jul 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.